Semax: Human Brain Imaging, No Cognitive Outcome

Semax is sold as a nootropic, and unlike most compounds in that market it has been studied in people. Fifty-two healthy participants had resting-state fMRI three times — before injection, and five and twenty minutes after — receiving semax, selank or placebo. Differences in functional connectivity were found, involving the right amygdala and temporal regions.^[1] Now the part that decides what it means: the study measured connectivity between brain regions. It did not measure memory, attention, or any task anybody performed.

What was actually measured

The design is careful. Regions of interest were predefined rather than fished for: the amygdala, central to anxiety regulation, and the dorsolateral prefrontal cortex, central to executive function including working memory, in both hemispheres. There was a placebo arm. Scans were repeated at fixed intervals. That is a properly constructed imaging study.^[1]

The findings were between-group and between-condition differences in functional connectivity between the right amygdala and a region spanning the fusiform, inferior and middle temporal and parahippocampal gyri. In plain terms: the correlation in activity between two parts of the brain changed after injection.

The rest of the evidence is rodents

Semax is an analog of a fragment of ACTH, and the mechanistic work behind it is animal neurochemistry — in rodents, it activates dopaminergic and serotoninergic brain systems.^[2] That is a coherent basis for a hypothesis about mood and cognition. It is a starting point for research, not a result about people.

Put the two together and the shape is familiar from across this market: a plausible mechanism in animals, a measurable signal in a human imaging study, and no trial testing whether anyone actually functions better. The missing study is not exotic. It is a randomized trial with a cognitive endpoint.

The question a nootropic has to answer is whether you performed better. An image of your brain is not an answer to it.

The same caveat as its sibling

Semax shares its evidence base, and much of its author group, with selank. Both compounds sit almost entirely within one national research literature, produced largely around the institute that developed them, without independent replication elsewhere. That is a weakness of evidentiary structure rather than of nationality, and it applies to both.

• Semax is not an approved medicine in the United States and is sold as a research chemical, without identity, purity or dose guarantees.
• The human study measured brain connectivity in healthy volunteers, with no cognitive or symptom endpoint.
• The mechanistic work is in rodents.
• ⚠ If you are seeking help with concentration, memory or mood, those are worth investigating properly — several have treatable causes, and none of them is diagnosed by a peptide vendor.